APP Pharmaceuticals (APPX) Receives Final Approval for Generic Kytril
APP Pharmaceuticals, Inc. (Nasdaq: APPX) received final approvals from the FDA of its Abbreviated New Drug Applications (ANDAs) for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL single dose, and 1mg/mL, 4mL multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril Injection.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
